Skip to content
2000
Volume 11, Issue 6
  • ISSN: 1567-2050
  • E-ISSN: 1875-5828

Abstract

Alzheimer’s disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose metabolism measured by FDG-PET in regions that decline in AD. MSDC-0160 (150 mg once daily; N=16) compared to placebo (N=13) for 12 weeks did not result in a significant difference in glucose metabolism in pre-defined regions when referenced to the pons or whole brain. However, glucose metabolism referenced to cerebellum was maintained in MSDC-0160 treated participants while it significantly declined for placebo patients in anterior and posterior cingulate, and parietal, lateral temporal, medial temporal cortices. Voxel-based analyses showed additional differences in FDG-PET related to MSDC-0160 treatment. These exploratory results suggest central effects of MSDC-0160 and provide a basis for further investigation of mTOT modulating insulin sensitizers in AD patients.

Loading

Article metrics loading...

/content/journals/car/10.2174/1567205011666140616113406
2014-07-01
2025-07-04
Loading full text...

Full text loading...

/content/journals/car/10.2174/1567205011666140616113406
Loading

  • Article Type:
    Research Article
Keyword(s): Alzheimer’s disease; FDG-PET; insulin resistance; insulin sensitizer; mTOT modulator
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test